Dergiler / Haseki Tıp Bülteni / 2018 / Cilt: 56 - Sayı: 2

Investigation of ErbB and Insulin Signaling Pathways in the Pathogenesis of Multiple Myeloma

Multipl Miyelom Patogenezinde ErbB ve İnsülin Sinyal Yolaklarının İncelenmesi

Sayfa
109–113
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

All these results will be useful to understand the pathogenesis of multiple myeloma.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim:Analysis of genes that play roles in multiple myeloma pathogenesis and their pathways are current research topics.
📊
Temel Bulgular & Veri:Methods: Bone marrow samples were taken from three healthy volunteers and 17 treatment-naive patients.
💡
Sonuç & Katkı:All these results will be useful to understand the pathogenesis of multiple myeloma.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aim:Analysis of genes that play roles in multiple myeloma pathogenesis and their pathways are current research topics. We aimed to detect expression of some genes in ErbB and insulin signaling pathways. Methods: Bone marrow samples were taken from three healthy volunteers and 17 treatment-naive patients. Firstly RNA isolation was made and then cDNA were synthesized. There are eight genes that are related to ErbB and insulin signaling pathways. Specific primers for these genes were designed. Gene expression analysis was performed by the real-time polymerase chain reaction method. Results: In the patient group, expressions of MTOR, RPTOR, PIK3CA, AKT1, ErbB4, PRKAR2A and PRKACB genes were detected to be 3-10 times up-regulated than in control group. There were no differences in the expression levels of RICTOR and GYS1 genes between control group and patient group. GYS1, PRKACB and PRKAR2A genes have been analyzed for the first time. Conclusion: In this study, PRKAR2A and PRKACB genes expressions were detected to be upregulated and this has not been reported in the literature before. MTOR, RPTOR, PIK3CA, AKT1, and ErbB4 genes expression were detected to be upregulated as has been reported in the literature. All these results will be useful to understand the pathogenesis of multiple myeloma.

Abstract

Amaç: Multiple myeloma patogenezinde rol oynayan genlerin ve ilgili yolakların moleküler düzeyde incelenmesi güncel bir araştırma alanıdır. ErbB ve insülin sinyal yolağında bulunan bazı genlerin ekspresyon çalışmasının yapılması amaçlandı. Yöntemler: Üç sağlıklı gönüllü ve 17 tedavisiz hastadan kemik iliği alındı, ilk olarak RNA izolasyonu yapıldı ve daha sonra cDNA sentezi yapıldı. ErbB ve insülin sinyal yolakları ile ilgili sekiz gen vardır, bu genler için spesifik primerler dizayn edilmiştir. Gen ekspresyon analizi, realtime polimeraz zincir reaksiyonu yöntemi ile gerçekleştirilmiştir. Bulgular: Hasta grubunda MTOR, RPTOR, PIK3CA, AKT1, ErbB4, PRKAR2A ve PRKACB genlerinin ekspresyonu kontrol grubuna göre 3-10 kat arttı. Kontrol grubu ile hasta grubu arasında RICTOR ve GYS1 genlerinin ekspresyon düzeylerinde farklılıklar gözlenmedi. GYS1, PRKACB ve PRKAR2A genleri ilk kez analiz edilmiştir. Sonuç: Bu çalışmada, PRKAR2A ve PRKACB gen ekspresyonlarının arttığı saptanmış ve daha önce literatürde bildirilmemiştir. MTOR, RPTOR, PIK3CA, AKT1, ErbB4 gen ekspresyonunun daha önce literatürde bildirildiği gibi ekspresyonlarının arttığı tespit edildi. Tüm bu sonuçlar multipl miyelomun patogenezini anlamak için faydalı olacaktır.

🔖

Bu Makaleye Atıf Yap

ÖZTÜRK, D., ÇOŞKUNPINAR, E. M., OSMANBAŞOĞLU, E., ÇETİN, G., YENEREL, M. N., AYER, M., EKMEKCI, C. G., ÜSTEK, D., ÇEFLE, K., PALANDUZ, Ş., ÖZTÜRK, Ş. (2018). Investigation of ErbB and Insulin Signaling Pathways in the Pathogenesis of Multiple Myeloma. Haseki Tıp Bülteni, Cilt: 56 - Sayı: 2, 109–113. https://ajindex.com/articles/267800

Kaynakça (15)

  1. Stella F, Pedrazzini E, Agazzoni M, et al. Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy. Cancer Invest 2015;33:496-504.
  2. Binsfeld M, Fostier K, Muller J, et al. Cellular immunotherapy in multiple myeloma: lessons from preclinical models. Biochim Biophys Acta 2014;1846:392-404.
  3. Cirit M, Uzum A, Ozen P, et al. The value of serum immunoglobulin free light chain assessment in patients with monoclonal gammopathies and acute renal failure. Turk J Haematol 2012;29:385-91.
  4. Fairfield H, Falank C, Avery L, et al. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci 2016;1364:32-51.
  5. Prideaux SM, Conway O’Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol 2014:864058. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013;88:360-76.
  6. Andrews SW, Kabrah S, May JE, et al. Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci 2013;70:110-20.
  7. Glavey SV, Manier S, Sacco A, et al. Epigenetics in Multiple Myeloma. Cancer Treat Res 2016;169:35-49.
  8. Garcia-Gomez A, Sanchez-Guijo F, Del Cañizo MC, et al. Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells 2014;6:322-43.
  9. Ni CY, Murphy MP, Golde TE, et al. gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179-81.
  10. Saghir FS, Rose IM, Dali AZ, et al. Gene expression profiling and cancer-related pathways in type I endometrial carcinoma. Int J Gynecol Cancer 2010;20:724-31.
  11. Paatero I, Elenius K. ErbB4 and its isoforms: patentable drug targets? Recent Pat DNA Gene Seq 2008;2:27-33.
  12. Mahtouk K, Hose D, Rème T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 2005;24:3512-24.
  13. Rossi M, Di Martino MT, Morelli E, et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:757-67.
  14. Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011;118:6860-70.
  15. Han K, Xu X, Chen G, et al. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J HematolOncol 2014;7:9. Azab F, Vali S, Abraham J, et a